Shares of Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) have earned a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $30.80.
A number of research analysts recently weighed in on the stock. HC Wainwright dropped their price objective on shares of Repare Therapeutics from $38.00 to $25.00 and set a "buy" rating for the company in a report on Thursday, November 17th. Capital One Financial assumed coverage on shares of Repare Therapeutics in a report on Friday. They issued an "overweight" rating and a $28.00 price objective for the company.
Get Repare Therapeutics alerts:Repare Therapeutics Price Performance
Shares of RPTX opened at $14.25 on Friday. Repare Therapeutics has a 1-year low of $8.06 and a 1-year high of $19.24. The stock has a market cap of $597.96 million, a PE ratio of -19.52 and a beta of 0.11. The firm has a 50-day simple moving average of $15.53 and a two-hundred day simple moving average of $13.95.
Repare Therapeutics (NASDAQ:RPTX – Get Rating) last announced its quarterly earnings results on Wednesday, November 9th. The company reported $1.71 earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $1.91. Repare Therapeutics had a negative net margin of 21.31% and a negative return on equity of 9.53%. The business had revenue of $112.55 million during the quarter, compared to analysts' expectations of $43.23 million. As a group, sell-side analysts expect that Repare Therapeutics will post -0.69 earnings per share for the current fiscal year.Insider Activity at Repare Therapeutics
In related news, Director Davis Jerel sold 250,000 shares of Repare Therapeutics stock in a transaction that occurred on Friday, December 9th. The shares were sold at an average price of $16.00, for a total value of $4,000,000.00. Following the completion of the transaction, the director now owns 2,094,451 shares in the company, valued at $33,511,216. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 33.60% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in RPTX. Bartlett & Co. LLC purchased a new position in Repare Therapeutics in the second quarter worth approximately $28,000. UBS Group AG lifted its position in shares of Repare Therapeutics by 26.3% during the 3rd quarter. UBS Group AG now owns 3,551 shares of the company's stock worth $43,000 after buying an additional 739 shares during the last quarter. Bpifrance SA purchased a new stake in shares of Repare Therapeutics during the 2nd quarter worth approximately $113,000. Tower Research Capital LLC TRC purchased a new stake in shares of Repare Therapeutics during the 3rd quarter worth approximately $113,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Repare Therapeutics during the 3rd quarter worth approximately $143,000. Hedge funds and other institutional investors own 78.19% of the company's stock.
Repare Therapeutics Company Profile
(Get Rating)
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
Read More
- Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
- Will LI Auto Be the Least Hated Chinese EV Stock in 2023?
- Which Streaming Service Stock is Best in 2023?
- Here's Why Snap Stock Can Double in 2023
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.